1. Home
  2. SKYT vs TSHA Comparison

SKYT vs TSHA Comparison

Compare SKYT & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SkyWater Technology Inc.

SKYT

SkyWater Technology Inc.

N/A

Current Price

$27.43

Market Cap

1.4B

Sector

Technology

ML Signal

N/A

Logo Taysha Gene Therapies Inc.

TSHA

Taysha Gene Therapies Inc.

N/A

Current Price

$4.59

Market Cap

1.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SKYT
TSHA
Founded
1991
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.2B
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
SKYT
TSHA
Price
$27.43
$4.59
Analyst Decision
Buy
Strong Buy
Analyst Count
5
9
Target Price
$26.50
$10.56
AVG Volume (30 Days)
872.7K
2.1M
Earning Date
05-26-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
1842.86
62.50
EPS
2.44
N/A
Revenue
$442,139,000.00
$8,333,000.00
Revenue This Year
$40.53
N/A
Revenue Next Year
$4.01
N/A
P/E Ratio
$10.74
N/A
Revenue Growth
29.18
N/A
52 Week Low
$5.67
$1.13
52 Week High
$36.07
$6.02

Technical Indicators

Market Signals
Indicator
SKYT
TSHA
Relative Strength Index (RSI) 40.82 47.58
Support Level $14.54 $4.41
Resistance Level $31.19 $5.16
Average True Range (ATR) 1.07 0.20
MACD -0.24 0.00
Stochastic Oscillator 0.00 35.71

Price Performance

Historical Comparison
SKYT
TSHA

About SKYT SkyWater Technology Inc.

SkyWater Technology Inc is a U.S.-based, independent, pure-play technology foundry that offers semiconductor development and manufacturing services from its fabrication facilities. In its technology as a service model, it leverages a foundation of proprietary technology, engineering to co-develop process technology intellectual property (IP) with its customers that enable disruptive concepts through its Technology Services for diverse microelectronics (integrated circuits) and related micro- and nanotechnology applications. It focuses on serving diversified, high-growth, end users in numerous vertical markets, including computation, aerospace and defense (A&D), automotive and transportation, bio-health, and industrial.

About TSHA Taysha Gene Therapies Inc.

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.

Share on Social Networks: